Resistencia viral y barrera genética de atazanavir
Viral resistance and genetic barrier of atazanavir
Carmen De Mendoza, Carolina Garrido, Ana Treviño, Lourdes Anta, Eva Poveda, Vicente Soriano
Servicio de Enfermedades Infecciosas. Hospital Carlos III. Madrid. España
Leído
5327
Vecesse ha leído el artículo
1441
Total PDF
3886
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0213005X08766175" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76617-5" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76617" "copyright" => "Elsevier España S.L.. Todos los derechos reservados" "copyrightAnyo" => "2008" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:28-33" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3492 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 2473 "PDF" => 1011 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X08766187" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76618-7" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76618" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:34-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1590 "formatos" => array:3 [ "EPUB" => 12 "HTML" => 1003 "PDF" => 575 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Perfil lipídico de atazanavir" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "34" "paginaFinal" => "40" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Lipid profile of atazanavir" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Esteban Martínez Chamorro" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Esteban Martínez" "apellidos" => "Chamorro" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766187?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766187/v1_201305090109/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X08766163" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(08)76616-3" "estado" => "S300" "fechaPublicacion" => "2008-12-01" "aid" => "76616" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2008;26 Supl 17:22-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1512 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1081 "PDF" => 423 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Atazanavir en terapias de rescate" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "22" "paginaFinal" => "27" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of atazanavir in rescue therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joaquín Portilla, Vicente Boix, Esperanza Merino, Sergio Reus" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Joaquín" "apellidos" => "Portilla" ] 1 => array:2 [ "nombre" => "Vicente" "apellidos" => "Boix" ] 2 => array:2 [ "nombre" => "Esperanza" "apellidos" => "Merino" ] 3 => array:2 [ "nombre" => "Sergio" "apellidos" => "Reus" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766163?idApp=UINPBA00004N" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766163/v1_201305090109/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Resistencia viral y barrera genética de atazanavir" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "28" "paginaFinal" => "33" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Carmen De Mendoza, Carolina Garrido, Ana Treviño, Lourdes Anta, Eva Poveda, Vicente Soriano" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Carmen De" "apellidos" => "Mendoza" ] 1 => array:2 [ "nombre" => "Carolina" "apellidos" => "Garrido" ] 2 => array:2 [ "nombre" => "Ana" "apellidos" => "Treviño" ] 3 => array:2 [ "nombre" => "Lourdes" "apellidos" => "Anta" ] 4 => array:2 [ "nombre" => "Eva" "apellidos" => "Poveda" ] 5 => array:3 [ "nombre" => "Vicente" "apellidos" => "Soriano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Enfermedades Infecciosas. Hospital Carlos III. Madrid. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Correspondencia: Dr. V. Soriano. Servicio de Enfermedades Infecciosas. Hospital Carlos III. Sinesio Delgado, 10. 28029 Madrid. España." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Viral resistance and genetic barrier of atazanavir" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec137561" "palabras" => array:4 [ 0 => "Atazanavir" 1 => "Resistencias" 2 => "Inhibidores de la proteasa" 3 => "VIH" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec137560" "palabras" => array:4 [ 0 => "Atazanavir" 1 => "Resistances" 2 => "Protease inhibitors" 3 => "HIV" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">La resistencia a los inhibidores de la proteasa (IP) generalmente es consecuencia de una mutación en el gen de la proteasa. Se han descrito distintos cambios para cada uno de los IP. La mutación I50L es la característica de resistencia al atazanavir (ATV). No produce resistencia cruzada con otros IP; por el contrario, aumenta la susceptibilidad a todos ellos (hipersusceptibilidad). Cuando los IP se administran conjuntamente con dosis bajas de ritonavir (r), la exposición a concentraciones más elevadas de IP hace necesaria la selección de múltiples mutaciones de resistencia en la proteasa para que haya una pérdida significativa de susceptibilidad. Para la mayoría de IP/r, incluido el ATV/r, se requieren ≥ 5 mutaciones en la proteasa para ocasionar un compromiso en la respuesta virológica. A pesar de tener una moderada barrera genética cuando no se potencia con ritonavir, la prolongada semivida del ATV minimiza el riesgo de resistencias en la práctica clínica.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Resistance to protease inhibitors (PI) is generally due to a mutation in the protease gene. Different changes have been described for each PI. The I 50L mutation is characteristic of resistance to atazanavir (ATV). It does not produce cross resistance to other PI; but it does increase susceptibility to all of them (hypersusceptibility). When PI are given concomitantly with low doses of ritonavir, the exposure to higher levels of PI requires that multiple resistance mutations have to be selected in the protease so that there is a significant loss of susceptibility. For the majority of PI/r, including ATV/r, ≥5 mutations in the protease are required to produce a compromise in the virological response. Despite having a moderate genetic barrier when not boosted with ritonavir, the prolonged half life of ATV minimises the risk of resistance in clinical practice.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:33 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Resistance to HIV protease inhibitors: mechanisms and clinical consequences" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. De Mendoza" 1 => "V. Soriano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Drug Metab" "fecha" => "2004" "volumen" => "5" "paginaInicial" => "321" "paginaFinal" => "328" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15320704" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir: the advent of a new generation of more convenient protease inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Barreiro" 1 => "A. Rendón" 2 => "S. Rodríguez-Nóvoa" 3 => "V. Soriano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/NBL2-R2G6-6V09-LL4C" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2005" "volumen" => "6" "paginaInicial" => "50" "paginaFinal" => "61" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15765311" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Jiménez-Nácher I, García B, Barreiro P, Rodriguez-Novoa S, Morello J, González-Lahoz J, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother. En prensa." ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HIV-1 drug resistance mutations: an updated framework for the second decade of HAART" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Shafer" 1 => "J. Schapiro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS Rev" "fecha" => "2008" "volumen" => "10" "paginaInicial" => "67" "paginaFinal" => "84" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18615118" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Hirsch" 1 => "H. Günthard" 2 => "J. Schapiro" 3 => "F. Brun-Vézinet" 4 => "B. Clotet" 5 => "S. Hammer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/589297" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "266" "paginaFinal" => "285" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18549313" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive patients receiving ATV-containing regimens" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Colonno" 1 => "R. Rose" 2 => "C. McLaren" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/386291" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2004" "volumen" => "189" "paginaInicial" => "1802" "paginaFinal" => "1810" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15122516" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P. Sista" 1 => "B. Wasikowski" 2 => "P. Lecocq" 3 => "T. Pattery" 4 => "L. Bacheler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcv.2008.03.023" "Revista" => array:6 [ "tituloSerie" => "J Clin Virol" "fecha" => "2008" "volumen" => "42" "paginaInicial" => "405" "paginaFinal" => "408" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18472298" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of once daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K. Squires" 1 => "A. Lazzarin" 2 => "J. Gatell" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2004" "volumen" => "36" "paginaInicial" => "1011" "paginaFinal" => "1019" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15247553" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Malan" 1 => "E. Krantz" 2 => "N. David" 3 => "V. Wirtz" 4 => "J. Hammond" 5 => "D. McGrath" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0b013e31815ace6a" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "161" "paginaFinal" => "167" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17971713" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. De Mendoza" 1 => "C. Garrido" 2 => "A. Corral" 3 => "G. Ramírez-Olivencia" 4 => "I. Jiménez-Nacher" 5 => "N. Zahonero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/aid.2005.0072" "Revista" => array:6 [ "tituloSerie" => "AIDS Res Hum Retroviruses" "fecha" => "2007" "volumen" => "23" "paginaInicial" => "879" "paginaFinal" => "885" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17678470" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Gatell" 1 => "D. Salmon-Ceron" 2 => "A. Lazzarin" 3 => "E. Van Wijngaerden" 4 => "F. Antunes" 5 => "C. Leen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2007" "volumen" => "44" "paginaInicial" => "1484" "paginaFinal" => "1492" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Soriano" 1 => "P. García-Gasco" 2 => "E. Vispo" 3 => "A. Ruiz-Sancho" 4 => "F. Blanco" 5 => "L. Martín-Carbonero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkm413" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2008" "volumen" => "61" "paginaInicial" => "200" "paginaFinal" => "205" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17999977" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Rodríguez-Nóvoa" 1 => "J. Morello" 2 => "P. Barreiro" 3 => "I. Maida" 4 => "P. García-Gascó" 5 => "E. Vispo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS Res Hum Retrovirus" "fecha" => "2008" "volumen" => "24" "paginaInicial" => "821" "paginaFinal" => "825" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Cleijsen" 1 => "M. Van de Ende" 2 => "F. Kroon" 3 => "F. Lunel" 4 => "P. Koopmans" 5 => "L. Gras" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkm298" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2007" "volumen" => "60" "paginaInicial" => "897" "paginaFinal" => "900" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17704117" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Rodríguez-Nóvoa" 1 => "L. Martín-Carbonero" 2 => "P. Barreiro" 3 => "G. González-Pardo" 4 => "I. Jiménez- Nácher" 5 => "J. González-Lahoz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e328011d7c1" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "41" "paginaFinal" => "46" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17148966" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C ->T polymorphism at the multidrug resistance gene 1" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Rodríguez Nóvoa" 1 => "P. Barreiro" 2 => "A. Rendón" 3 => "A. Barrios" 4 => "A. Corral" 5 => "I. Jiménez-Nacher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/499056" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2006" "volumen" => "42" "paginaInicial" => "291" "paginaFinal" => "295" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16355344" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Barreiro" 1 => "S. Rodríguez-Novoa" 2 => "P. Labarga" 3 => "A. Ruiz" 4 => "I. Jiménez-Nácher" 5 => "L. Martín-Carbonero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/512086" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2007" "volumen" => "195" "paginaInicial" => "973" "paginaFinal" => "979" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17330787" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of virological response to atazanavir in protease inhibitor-experienced patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Barrios" 1 => "A.L. Rendón" 2 => "O. Gallego" 3 => "L. Martín-Carbonero" 4 => "L. Valer" 5 => "P. Ríos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/3HL3-HHBD-WKLR-XELL" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2004" "volumen" => "5" "paginaInicial" => "201" "paginaFinal" => "205" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15472794" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Solas" 1 => "P. Colson" 2 => "I. Ravaux" 3 => "I. Poizot-Martin" 4 => "J. Moreau" 5 => "B. Lacarelle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0b013e318164226a" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2008" "volumen" => "48" "paginaInicial" => "177" "paginaFinal" => "180" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18197119" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Smith" 1 => "W. Weinberg" 2 => "E. De Jesus" 3 => "M. Fischl" 4 => "Q. Liao" 5 => "L. Ross" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1742-6405-5-5" "Revista" => array:6 [ "tituloSerie" => "AIDS Res Ther" "fecha" => "2008" "volumen" => "5" "paginaInicial" => "5" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18373851" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Molina JM, Andrade-Villanueva J, Echevarria J. Efficacy and safety of once daily atazanavir/ritonavir compared to twice daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1-infected subjects. CROI 2008, Boston. Abstract 37." ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Virological failure and subsequent resistance profiles in individuals exposed to atazanavir" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Stebbing" 1 => "B. Nathan" 2 => "R. Jones" 3 => "A. McKenna" 4 => "T. Powles" 5 => "M. Bower" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e3282742000" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "1826" "paginaFinal" => "1828" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17690587" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Johnson" 1 => "B. Grinsztejn" 2 => "C. Rodriguez" 3 => "J. Coco" 4 => "E. De Jesus" 5 => "A. Lazzarin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2005" "volumen" => "19" "paginaInicial" => "685" "paginaFinal" => "694" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of six different ritonavir-boosted protease inhibitor-ba- sed regimens in heavily antiretroviral-experienced HIV-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. De Mendoza" 1 => "L. Valer" 2 => "E. Ribera" 3 => "P. Barreiro" 4 => "L. Martín-Carbonero" 5 => "G. Ramirez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2006" "volumen" => "7" "paginaInicial" => "163" "paginaFinal" => "171" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Cuzin" 1 => "P. Flandre" 2 => "P. Pugliese" 3 => "C. Duvivier" 4 => "Y. Yazdanpanah" 5 => "E. Billaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1310/hct0903-147" "Revista" => array:6 [ "tituloSerie" => "HIV Clin Trials" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "147" "paginaFinal" => "151" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18547901" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Sahali" 1 => "M.L. Chaix" 2 => "J.F. Delfraissy" 3 => "J. Ghosn" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS Rev" "fecha" => "2008" "volumen" => "10" "paginaInicial" => "4" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18385776" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of compartment penetration in PI-monotherapy: the Atazanavir- Ritonavir Monomaintenance (ATARITMO) Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Vernazza" 1 => "S. Daneel" 2 => "V. Schiffer" 3 => "L. Decosterd" 4 => "W. Fierz" 5 => "T. Klimkait" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "1309" "paginaFinal" => "1315" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "More frequent detection of lopinavir resistance by single genome sequencing at virological failure of lopinavir/ritonavir maintenance therapy in the OK04 study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. McKinnon" 1 => "R. Delgado" 2 => "J.R. Arribas" 3 => "F. Pulido" 4 => "J. Mellors" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Antivir Ther" "fecha" => "2008" "volumen" => "13" "numero" => "Suppl 3" "paginaInicial" => "A87" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "O. Karlström" 1 => "F. Josephson" 2 => "A. Sönnerborg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAI.0b013e31802e2940" "Revista" => array:6 [ "tituloSerie" => "J Acquir Immune Defic Syndr" "fecha" => "2007" "volumen" => "44" "paginaInicial" => "417" "paginaFinal" => "422" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17159658" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular basis for increased susceptibility of isolates with atazanavir resistance- conferring substitution I50L to other protease inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Yanchunas" 1 => "D. Langley" 2 => "L. Tao" 3 => "R. Rose" 4 => "J. Friborg" 5 => "R. Colonno" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.49.9.3825-3832.2005" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2005" "volumen" => "49" "paginaInicial" => "3825" "paginaFinal" => "3832" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16127059" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Holguín" 1 => "E. Ramirez de Arellano" 2 => "P. Rivas" 3 => "V. Soriano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS Rev" "fecha" => "2006" "volumen" => "8" "paginaInicial" => "98" "paginaFinal" => "107" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16848277" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The CASTLE study 48 weeks results: the impact of HIV subtypes and baseline resistance on treatment outcomes and the emergence of resistance" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "For the BMSAI424138 Study Group" "etal" => false "autores" => array:5 [ 0 => "M. Lataillade" 1 => "J.M. Molina" 2 => "A. Thiry" 3 => "M. Mancini" 4 => "D. McGrath" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Antivir Ther" "fecha" => "2008" "volumen" => "13" "numero" => "Suppl 3" "paginaInicial" => "A135" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "B. Rodés" 1 => "J. Sheldon" 2 => "C. Toro" 3 => "V. Jiménez" 4 => "M.A. Alvarez" 5 => "V. Soriano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dkl034" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother" "fecha" => "2006" "volumen" => "57" "paginaInicial" => "709" "paginaFinal" => "713" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16464891" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/0000002600000S17/v1_201305090109/S0213005X08766175/v1_201305090109/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000002600000S17/v1_201305090109/S0213005X08766175/v1_201305090109/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X08766175?idApp=UINPBA00004N" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Octubre | 3 | 10 | 13 |
| 2024 Septiembre | 12 | 7 | 19 |
| 2024 Agosto | 17 | 5 | 22 |
| 2024 Julio | 7 | 3 | 10 |
| 2024 Junio | 9 | 2 | 11 |
| 2024 Mayo | 9 | 3 | 12 |
| 2024 Abril | 9 | 2 | 11 |
| 2024 Marzo | 12 | 4 | 16 |
| 2024 Febrero | 7 | 2 | 9 |
| 2024 Enero | 8 | 2 | 10 |
| 2023 Diciembre | 10 | 2 | 12 |
| 2023 Noviembre | 11 | 2 | 13 |
| 2023 Octubre | 11 | 1 | 12 |
| 2023 Septiembre | 12 | 1 | 13 |
| 2023 Agosto | 8 | 1 | 9 |
| 2023 Julio | 5 | 2 | 7 |
| 2023 Junio | 27 | 7 | 34 |
| 2023 Mayo | 22 | 0 | 22 |
| 2023 Abril | 26 | 0 | 26 |
| 2023 Marzo | 17 | 1 | 18 |
| 2023 Febrero | 13 | 4 | 17 |
| 2023 Enero | 12 | 2 | 14 |
| 2022 Diciembre | 18 | 2 | 20 |
| 2022 Noviembre | 28 | 12 | 40 |
| 2022 Octubre | 22 | 15 | 37 |
| 2022 Septiembre | 24 | 11 | 35 |
| 2022 Agosto | 21 | 7 | 28 |
| 2022 Julio | 19 | 12 | 31 |
| 2022 Junio | 13 | 8 | 21 |
| 2022 Mayo | 20 | 13 | 33 |
| 2022 Abril | 30 | 19 | 49 |
| 2022 Marzo | 29 | 6 | 35 |
| 2022 Febrero | 36 | 13 | 49 |
| 2022 Enero | 58 | 11 | 69 |
| 2021 Diciembre | 53 | 9 | 62 |
| 2021 Noviembre | 45 | 16 | 61 |
| 2021 Octubre | 35 | 13 | 48 |
| 2021 Septiembre | 20 | 6 | 26 |
| 2021 Agosto | 28 | 8 | 36 |
| 2021 Julio | 42 | 7 | 49 |
| 2021 Junio | 30 | 5 | 35 |
| 2021 Mayo | 43 | 11 | 54 |
| 2021 Abril | 131 | 19 | 150 |
| 2021 Marzo | 40 | 11 | 51 |
| 2021 Febrero | 19 | 10 | 29 |
| 2021 Enero | 26 | 15 | 41 |
| 2020 Diciembre | 30 | 11 | 41 |
| 2020 Noviembre | 33 | 9 | 42 |
| 2020 Octubre | 39 | 11 | 50 |
| 2020 Septiembre | 13 | 4 | 17 |
| 2020 Agosto | 23 | 6 | 29 |
| 2020 Julio | 29 | 18 | 47 |
| 2020 Junio | 24 | 4 | 28 |
| 2020 Mayo | 51 | 14 | 65 |
| 2020 Abril | 32 | 8 | 40 |
| 2020 Marzo | 31 | 16 | 47 |
| 2020 Febrero | 23 | 16 | 39 |
| 2020 Enero | 11 | 9 | 20 |
| 2019 Diciembre | 20 | 22 | 42 |
| 2019 Noviembre | 21 | 3 | 24 |
| 2019 Octubre | 13 | 6 | 19 |
| 2019 Septiembre | 11 | 12 | 23 |
| 2019 Agosto | 7 | 10 | 17 |
| 2019 Julio | 14 | 14 | 28 |
| 2019 Junio | 35 | 62 | 97 |
| 2019 Mayo | 110 | 117 | 227 |
| 2019 Abril | 36 | 49 | 85 |
| 2019 Marzo | 14 | 21 | 35 |
| 2019 Febrero | 6 | 36 | 42 |
| 2019 Enero | 6 | 33 | 39 |
| 2018 Diciembre | 5 | 37 | 42 |
| 2018 Noviembre | 3 | 5 | 8 |
| 2018 Octubre | 10 | 5 | 15 |
| 2018 Septiembre | 2 | 14 | 16 |
| 2018 Agosto | 5 | 28 | 33 |
| 2018 Julio | 5 | 17 | 22 |
| 2018 Junio | 8 | 22 | 30 |
| 2018 Mayo | 9 | 10 | 19 |
| 2018 Abril | 3 | 14 | 17 |
| 2018 Marzo | 4 | 13 | 17 |
| 2018 Febrero | 5 | 7 | 12 |
| 2018 Enero | 1 | 5 | 6 |
| 2017 Diciembre | 9 | 5 | 14 |
| 2017 Noviembre | 4 | 4 | 8 |
| 2017 Octubre | 4 | 4 | 8 |
| 2017 Septiembre | 4 | 12 | 16 |
| 2017 Agosto | 9 | 3 | 12 |
| 2017 Julio | 3 | 8 | 11 |
| 2017 Junio | 7 | 13 | 20 |
| 2017 Mayo | 7 | 10 | 17 |
| 2017 Abril | 3 | 3 | 6 |
| 2017 Marzo | 10 | 11 | 21 |
| 2017 Febrero | 4 | 0 | 4 |
| 2017 Enero | 9 | 0 | 9 |
| 2016 Diciembre | 4 | 2 | 6 |
| 2016 Noviembre | 7 | 2 | 9 |
| 2016 Octubre | 14 | 4 | 18 |
| 2016 Septiembre | 14 | 7 | 21 |
| 2016 Agosto | 4 | 0 | 4 |
| 2016 Julio | 31 | 1 | 32 |
| 2016 Junio | 80 | 30 | 110 |
| 2016 Mayo | 56 | 26 | 82 |
| 2016 Abril | 27 | 20 | 47 |
| 2016 Marzo | 22 | 21 | 43 |
| 2016 Febrero | 15 | 19 | 34 |
| 2016 Enero | 25 | 19 | 44 |
| 2015 Diciembre | 54 | 17 | 71 |
| 2015 Noviembre | 43 | 16 | 59 |
| 2015 Octubre | 32 | 20 | 52 |
| 2015 Septiembre | 54 | 17 | 71 |
| 2015 Agosto | 49 | 6 | 55 |
| 2015 Julio | 44 | 9 | 53 |
| 2015 Junio | 49 | 4 | 53 |
| 2015 Mayo | 62 | 11 | 73 |
| 2015 Abril | 30 | 12 | 42 |
| 2015 Marzo | 53 | 11 | 64 |
| 2015 Febrero | 33 | 4 | 37 |
| 2015 Enero | 44 | 7 | 51 |
| 2014 Diciembre | 41 | 6 | 47 |
| 2014 Noviembre | 60 | 3 | 63 |
| 2014 Octubre | 71 | 2 | 73 |
| 2014 Septiembre | 43 | 8 | 51 |
| 2014 Agosto | 59 | 2 | 61 |
| 2014 Julio | 51 | 5 | 56 |
| 2014 Junio | 35 | 3 | 38 |
| 2014 Mayo | 43 | 1 | 44 |
| 2014 Abril | 26 | 1 | 27 |
| 2014 Marzo | 29 | 1 | 30 |
| 2014 Febrero | 36 | 2 | 38 |
| 2014 Enero | 27 | 4 | 31 |
| 2013 Diciembre | 29 | 2 | 31 |
| 2013 Noviembre | 28 | 8 | 36 |
| 2013 Octubre | 25 | 5 | 30 |
| 2013 Septiembre | 17 | 8 | 25 |
| 2013 Agosto | 18 | 10 | 28 |
| 2013 Julio | 17 | 2 | 19 |
| 2008 Diciembre | 523 | 0 | 523 |
Mostrar todo
